Eli Lilly and Company (NYSE:LLY) Shares Acquired by Atlas Brown Inc.

Atlas Brown Inc. boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 2.3% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,976 shares of the company’s stock after acquiring an additional 45 shares during the quarter. Atlas Brown Inc.’s holdings in Eli Lilly and Company were worth $1,789,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in LLY. Lynx Investment Advisory acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $32,000. Core Wealth Advisors Inc. boosted its position in shares of Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after buying an additional 32 shares during the period. Activest Wealth Management acquired a new stake in Eli Lilly and Company in the first quarter valued at approximately $39,000. Tidemark LLC acquired a new stake in Eli Lilly and Company during the 4th quarter valued at $29,000. Finally, Redmont Wealth Advisors LLC purchased a new stake in shares of Eli Lilly and Company during the first quarter worth about $40,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on LLY. Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and lifted their price target for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Guggenheim raised their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday. Jefferies Financial Group boosted their price target on Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Finally, Wells Fargo & Company increased their price objective on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a report on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $956.88.

Eli Lilly and Company Stock Up 0.2 %

Shares of Eli Lilly and Company stock opened at $954.19 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53. The stock has a 50-day moving average price of $884.83 and a 200 day moving average price of $812.10. The company has a market cap of $906.87 billion, a P/E ratio of 140.53, a P/E/G ratio of 1.81 and a beta of 0.41.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.54%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is presently 76.58%.

Insider Transactions at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the transaction, the insider now owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Johna Norton sold 7,056 shares of the business’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.38, for a total transaction of $5,781,545.28. Following the completion of the sale, the executive vice president now owns 25,428 shares of the company’s stock, valued at $20,835,194.64. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,122,141 shares of company stock valued at $991,938,411. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.